Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C

David R. Nelson, Vinod Rustgi, Vijayan Balan, Mark S. Sulkowski, Gary L. Davis, Andrew J. Muir, Louis Lambiase, Rolland C. Dickson, Russell H. Weisner, Michele Fiscella, Patrick W. Cronin, Erik Pulkstenis, John G. McHutchison, G. Mani Subramanian

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background & Aims: Pegylated interferon alfa-2a/2b is used in combination with ribavirin to treat patients with chronic hepatitis C (CHC), although many do not achieve a sustained virologic response (SVR). Albinterferon alfa-2b, a recombinant protein consisting of interferon alfa-2b fused to human albumin, may increase drug exposure. This phase 2 study evaluated the safety/efficacy of albinterferon in CHC patients who had not responded to interferon-based regimens. Methods: A total of 115 patients were assigned to 5 groups given 1200 μg albinterferon every 4 weeks or 900, 1200, 1500, or 1800 μg every 2 weeks, plus oral ribavirin, for 48 weeks. The primary efficacy end point was achievement of an SVR after 24 weeks. Treatment was extended to 72 weeks for 6 slow responders who were negative for hepatitis C virus RNA after 24 weeks. Results: The types of adverse events were similar across groups; the overall discontinuation rate as a result of adverse events was 10.4%. Reductions in absolute neutrophil counts were less frequent in the every 4 weeks group and comparable among the every 2 weeks groups. The overall SVR rate was 17% (11% for previous nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection). An SVR occurred in 3 of 6 slow responders by 72 weeks. The greatest reductions in hepatitis C virus RNA in nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection were observed in the 1800-μg group. Conclusions: In patients with CHC who did not respond to interferon-based regimens, higher doses of albinterferon had significant early antiviral activity and a low incidence of adverse events, with the types of adverse events similar to those observed with interferon.

Original languageEnglish (US)
Pages (from-to)212-218
Number of pages7
JournalClinical Gastroenterology and Hepatology
Volume7
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferons
Antiviral Agents
Safety
interferon alfa-2b
Interferon-alpha
Hepacivirus
Genotype
RNA
Infection
Recombinant Proteins
Albumins
Neutrophils
Sustained Virologic Response
albinterferon alfa-2b
Incidence
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Nelson, D. R., Rustgi, V., Balan, V., Sulkowski, M. S., Davis, G. L., Muir, A. J., ... Subramanian, G. M. (2009). Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 7(2), 212-218. https://doi.org/10.1016/j.cgh.2008.10.035

Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C. / Nelson, David R.; Rustgi, Vinod; Balan, Vijayan; Sulkowski, Mark S.; Davis, Gary L.; Muir, Andrew J.; Lambiase, Louis; Dickson, Rolland C.; Weisner, Russell H.; Fiscella, Michele; Cronin, Patrick W.; Pulkstenis, Erik; McHutchison, John G.; Subramanian, G. Mani.

In: Clinical Gastroenterology and Hepatology, Vol. 7, No. 2, 01.02.2009, p. 212-218.

Research output: Contribution to journalArticle

Nelson, DR, Rustgi, V, Balan, V, Sulkowski, MS, Davis, GL, Muir, AJ, Lambiase, L, Dickson, RC, Weisner, RH, Fiscella, M, Cronin, PW, Pulkstenis, E, McHutchison, JG & Subramanian, GM 2009, 'Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C', Clinical Gastroenterology and Hepatology, vol. 7, no. 2, pp. 212-218. https://doi.org/10.1016/j.cgh.2008.10.035
Nelson, David R. ; Rustgi, Vinod ; Balan, Vijayan ; Sulkowski, Mark S. ; Davis, Gary L. ; Muir, Andrew J. ; Lambiase, Louis ; Dickson, Rolland C. ; Weisner, Russell H. ; Fiscella, Michele ; Cronin, Patrick W. ; Pulkstenis, Erik ; McHutchison, John G. ; Subramanian, G. Mani. / Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C. In: Clinical Gastroenterology and Hepatology. 2009 ; Vol. 7, No. 2. pp. 212-218.
@article{cf480f26dbf1473b9039678056bd2ffb,
title = "Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C",
abstract = "Background & Aims: Pegylated interferon alfa-2a/2b is used in combination with ribavirin to treat patients with chronic hepatitis C (CHC), although many do not achieve a sustained virologic response (SVR). Albinterferon alfa-2b, a recombinant protein consisting of interferon alfa-2b fused to human albumin, may increase drug exposure. This phase 2 study evaluated the safety/efficacy of albinterferon in CHC patients who had not responded to interferon-based regimens. Methods: A total of 115 patients were assigned to 5 groups given 1200 μg albinterferon every 4 weeks or 900, 1200, 1500, or 1800 μg every 2 weeks, plus oral ribavirin, for 48 weeks. The primary efficacy end point was achievement of an SVR after 24 weeks. Treatment was extended to 72 weeks for 6 slow responders who were negative for hepatitis C virus RNA after 24 weeks. Results: The types of adverse events were similar across groups; the overall discontinuation rate as a result of adverse events was 10.4{\%}. Reductions in absolute neutrophil counts were less frequent in the every 4 weeks group and comparable among the every 2 weeks groups. The overall SVR rate was 17{\%} (11{\%} for previous nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection). An SVR occurred in 3 of 6 slow responders by 72 weeks. The greatest reductions in hepatitis C virus RNA in nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection were observed in the 1800-μg group. Conclusions: In patients with CHC who did not respond to interferon-based regimens, higher doses of albinterferon had significant early antiviral activity and a low incidence of adverse events, with the types of adverse events similar to those observed with interferon.",
author = "Nelson, {David R.} and Vinod Rustgi and Vijayan Balan and Sulkowski, {Mark S.} and Davis, {Gary L.} and Muir, {Andrew J.} and Louis Lambiase and Dickson, {Rolland C.} and Weisner, {Russell H.} and Michele Fiscella and Cronin, {Patrick W.} and Erik Pulkstenis and McHutchison, {John G.} and Subramanian, {G. Mani}",
year = "2009",
month = "2",
day = "1",
doi = "10.1016/j.cgh.2008.10.035",
language = "English (US)",
volume = "7",
pages = "212--218",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C

AU - Nelson, David R.

AU - Rustgi, Vinod

AU - Balan, Vijayan

AU - Sulkowski, Mark S.

AU - Davis, Gary L.

AU - Muir, Andrew J.

AU - Lambiase, Louis

AU - Dickson, Rolland C.

AU - Weisner, Russell H.

AU - Fiscella, Michele

AU - Cronin, Patrick W.

AU - Pulkstenis, Erik

AU - McHutchison, John G.

AU - Subramanian, G. Mani

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Background & Aims: Pegylated interferon alfa-2a/2b is used in combination with ribavirin to treat patients with chronic hepatitis C (CHC), although many do not achieve a sustained virologic response (SVR). Albinterferon alfa-2b, a recombinant protein consisting of interferon alfa-2b fused to human albumin, may increase drug exposure. This phase 2 study evaluated the safety/efficacy of albinterferon in CHC patients who had not responded to interferon-based regimens. Methods: A total of 115 patients were assigned to 5 groups given 1200 μg albinterferon every 4 weeks or 900, 1200, 1500, or 1800 μg every 2 weeks, plus oral ribavirin, for 48 weeks. The primary efficacy end point was achievement of an SVR after 24 weeks. Treatment was extended to 72 weeks for 6 slow responders who were negative for hepatitis C virus RNA after 24 weeks. Results: The types of adverse events were similar across groups; the overall discontinuation rate as a result of adverse events was 10.4%. Reductions in absolute neutrophil counts were less frequent in the every 4 weeks group and comparable among the every 2 weeks groups. The overall SVR rate was 17% (11% for previous nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection). An SVR occurred in 3 of 6 slow responders by 72 weeks. The greatest reductions in hepatitis C virus RNA in nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection were observed in the 1800-μg group. Conclusions: In patients with CHC who did not respond to interferon-based regimens, higher doses of albinterferon had significant early antiviral activity and a low incidence of adverse events, with the types of adverse events similar to those observed with interferon.

AB - Background & Aims: Pegylated interferon alfa-2a/2b is used in combination with ribavirin to treat patients with chronic hepatitis C (CHC), although many do not achieve a sustained virologic response (SVR). Albinterferon alfa-2b, a recombinant protein consisting of interferon alfa-2b fused to human albumin, may increase drug exposure. This phase 2 study evaluated the safety/efficacy of albinterferon in CHC patients who had not responded to interferon-based regimens. Methods: A total of 115 patients were assigned to 5 groups given 1200 μg albinterferon every 4 weeks or 900, 1200, 1500, or 1800 μg every 2 weeks, plus oral ribavirin, for 48 weeks. The primary efficacy end point was achievement of an SVR after 24 weeks. Treatment was extended to 72 weeks for 6 slow responders who were negative for hepatitis C virus RNA after 24 weeks. Results: The types of adverse events were similar across groups; the overall discontinuation rate as a result of adverse events was 10.4%. Reductions in absolute neutrophil counts were less frequent in the every 4 weeks group and comparable among the every 2 weeks groups. The overall SVR rate was 17% (11% for previous nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection). An SVR occurred in 3 of 6 slow responders by 72 weeks. The greatest reductions in hepatitis C virus RNA in nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection were observed in the 1800-μg group. Conclusions: In patients with CHC who did not respond to interferon-based regimens, higher doses of albinterferon had significant early antiviral activity and a low incidence of adverse events, with the types of adverse events similar to those observed with interferon.

UR - http://www.scopus.com/inward/record.url?scp=58849122392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849122392&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2008.10.035

DO - 10.1016/j.cgh.2008.10.035

M3 - Article

C2 - 19061971

AN - SCOPUS:58849122392

VL - 7

SP - 212

EP - 218

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 2

ER -